| Bioactivity | DHODH-IN-11 (Compound 14b) is a Leflunomide derivative and a weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.03[1]. |
| Target | pKa: 5.03 (DHODH) |
| Invitro | Designed a compound structurally related to Leflunomide, containing the furazan ring (Compound 14a), is designed. Compound 14a undergo ring 4 scission under physiological pH conditions to afford the corresponding cyano-oximes DHODH-IN-11 (Compound 14b). DHODH-IN-14 has been assayed as a DHODH inhibitor; its low potency is probably due to the unfavourable stereochemistry of the oxime substructure[1]. |
| Name | DHODH-IN-11 |
| CAS | 1263303-95-2 |
| Formula | C15H11N3O2 |
| Molar Mass | 265.27 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | -20°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Giorgis M, et al. 1,2,5-Oxadiazole analogues of leflunomide and related compounds. Eur J Med Chem. 2011 Jan;46(1):383-92. |
DHODH-IN-11
CAS: 1263303-95-2 F: C15H11N3O2 W: 265.27
DHODH-IN-11 (Compound 14b) is a Leflunomide derivative and a weak dihydroorotate dehydrogenase (DHODH) inhibitor with a
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.